High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
Sarah WangElizabeth E HwangRajarshi GuhaAllison F O'NeillNicole MelongChansey J VeinotteAmy Conway SaurKellsey WuertheleMin ShenCrystal McKnightGabriela AlexeMadeleine E LemieuxAmy WangEmma HughesXin XuMatthew B BoxerMatthew D HallAndrew KungJason N BermanMindy I DavisKimberly StegmaierBrian D CromptonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
FAK and Aurora kinase B inhibitors synergistically impair Ewing sarcoma cell viability and significantly inhibit tumor progression. This study provides preclinical support for the consideration of a clinical trial testing the safety and efficacy of this combination for patients with Ewing sarcoma.
Keyphrases
- high throughput
- clinical trial
- protein kinase
- tyrosine kinase
- poor prognosis
- genome wide
- randomized controlled trial
- stem cells
- cell therapy
- study protocol
- cell migration
- open label
- escherichia coli
- drug delivery
- cancer therapy
- staphylococcus aureus
- pseudomonas aeruginosa
- cystic fibrosis
- candida albicans
- phase iii
- smoking cessation